Drug Trial Radar · NCT05876767
Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Oct 15, 2021
Primary completion
Dec 12, 2023
Study completion Dec 12, 2023
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase 1 study will assess the safety and tolerability, and characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of SAR444336 in healthy subjects following single- and repeated-dose administrations as a first step in clinical development prior to administering this new investigational medicinal product (IMP) to patients.
Conditions
- Healthy Volunteer
Interventions
SAR444336Drug
Single or repeated dose subcutaneous injection
PlaceboDrug
Single or repeated dose subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of subjects with treatment-emergent adverse events (TEAEs)Time frame: Until Day 43
- Part 2: Number of subjects with treatment-emergent adverse events (TEAEs)Time frame: Until Day 85
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number :5280001
Leiden, Leiden, Netherlands
Investigational Site Number :5280002
Groningen, Provincie Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.